lae102
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 25, 2024 (NCT06493084)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Activin receptor type-2AINHIBITOR
ACVR2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07230496 | Phase 1 | Dec 31, 2025 | Laekna Limited |
| NCT06908707 | Phase 1 | Apr 22, 2025 | Eli Lilly, Fortrea Clinical Research Unit Inc., Laekna Limited |
| NCT06493084 | Phase 1 | Jun 25, 2024 | Laekna Limited |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Laekna Limited | For profit | 3 | 3 | 1 | 2024 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2025 |
| Fortrea Clinical Research Unit Inc. | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1